Precision BioSciences, Inc. (DTIL)

In the past six months, Precision BioSciences, Inc. announced an underwritten public offering on November 10, 2025, to raise approximately $75 million. The stock price has experienced volatility, including a 10% increase on March 17, 2026, and a 9.97% decrease on March 30, 2026. Over the past year, DTIL's share price has been volatile compared to the US market.

Precision BioSciences, Inc.'s products and services do not typically experience demand seasonality. The demand for its therapies is driven by the prevalence and progression of the diseases they aim to treat, as well as the success of clinical trials and regulatory approvals.

Precision BioSciences, Inc., headquartered in Durham, North Carolina, is a publicly traded American clinical-stage gene editing company operating within the Biotechnology industry. The company is dedicated to improving life through its proprietary ARCUS® genome editing platform, designed for in vivo gene editing therapies. The ARCUS Genome Editing Platform is the core technology used for DNA genome insertion, removal, and repair. PBGENE-HBV is a therapy in development for chronic hepatitis B virus, aiming to eliminate covalently closed circular DNA. PBGENE-DMD is a gene editing therapy for Duchenne muscular dystrophy, with plans to file an IND or CTA by the end of 2025. PBGENE-3243 is in development for the treatment of m.3243 associated mitochondrial diseases. iECURE-OTC is a therapy for ornithine transcarbamylase deficiency, developed through a collaboration with iECURE, Inc. Precision BioSciences has partnered with TG Cell Therapy, Inc. to develop azercabtagene zapreleucel for autoimmune diseases.

Precision BioSciences, Inc. is headquartered in Durham, North Carolina, United States, with operations and a focus on developing therapies primarily within the United States.

In the past year, Precision BioSciences' brand reputation indicates a "Hold" consensus rating based on three Wall Street analysts. The company's stock has been noted for its volatility over the past three months compared to the US market. Positive preclinical data for its PBGENE-DMD program, presented in March 2025, highlighted the potential for a first-in-class treatment for Duchenne muscular dystrophy, which could positively impact its scientific and brand reputation.

Precision BioSciences, Inc. has a significant number of institutional owners and shareholders. As of April 9, 2026, 75 institutional owners and shareholders held a total of 15,096,313 shares, representing approximately 47.22% of the shares outstanding. Major institutional owners include Empery Asset Management, LP, Standard Life Aberdeen plc, and Octagon Capital Advisors LP.